TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01093534
Drug: solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT00662779
Drug: arformoterol
Normalized name: Arformoterol
DrugBank: Arformoterol (DB01274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mcg arformoterol nebulizer
Study: NCT00662779
Drug: formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol 12 mcg/inhalation, dry powder inhaler
Study: NCT00916630
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intravenously over a 10 to 20 minute period once every 14 days.
Study: NCT02399657
Drug: Intravitreal dexamethasone 0.7mg implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
Study: NCT03603418
Drug: Dexamethasone Sodium Phosphate
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.
Study: NCT04563000
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
Study: NCT01868451
Drug: Brentuximab vedotin (SGN-35)
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01868451
Drug: Vinblastine Sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01868451
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02216487
Drug: HA-Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
Study: NCT00716053
Drug: BLVR
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BLVR 20 mL
Study: NCT00408603
Drug: Voreloxin Injection
Normalized name: Voreloxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
Study: NCT01786239
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Study: NCT01786239
Drug: Omega-3 capsules
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
Study: NCT03990038
Drug: Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group C receive the intervention Group U receives the placebo See arm description
Study: NCT00331162
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
Study: NCT00331162
Drug: Anti-Thymocyte Globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr \< 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature \> 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours
Study: NCT00012467
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012467
Drug: Flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012467
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012467
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012467
Drug: Interferon gamma-1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02694848
Drug: Salvianolate injection
Normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
Study: NCT02694848
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
Study: NCT02749656
Drug: 0.25% Desoximetasone cream (Topoxy®)
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apply on the scalp psoriasis lesion twice a day
Study: NCT02749656
Drug: 0.25% Desoximetasone cream (Topicorte®)
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apply on the scalp psoriasis lesion twice a day
Study: NCT01298518
Drug: PF-04620110
Normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of PF-04620110 given once daily
Study: NCT01298518
Drug: PF-04620110
Normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of PF-04620110 given twice daily
Study: NCT00516243
Drug: defined green tea catechin extract
Normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03125213
Drug: AL-3778
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-3778 tablets
Study: NCT03125213
Drug: Peginterferon Alfa-2A
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon Alfa-2A for subcutaneous injection
Study: NCT02038920
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV injection
Study: NCT02038920
Drug: Vedolizumab placebo
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab placebo-matching IV infusion
Study: NCT00764868
Drug: Lisdexamfetamine Dimesylate (LDX)
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: optimal dose of 30, 50 or 70 mg once daily
Study: NCT04221035
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/m2 (max dose 2 mg)
Study: NCT04221035
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2
Study: NCT02211352
Drug: Korean Red Ginseng Capsules
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Study: NCT03471871
Drug: Lemborexant 10 mg
Normalized name: lemborexant 10 MG
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Study: NCT04221035
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 175 mg/m2
Study: NCT04221035
Drug: Vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/m2/day (max dose 6 mg)
Study: NCT04221035
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/m2/day
Study: NCT04221035
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1500 mg/m2/day
Study: NCT04221035
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: \< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
Study: NCT04221035
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
Study: NCT04221035
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg/m2/day over 2 hours
Study: NCT04221035
Drug: Dinutuximab Beta
Normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
Study: NCT04221035
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m2/24h
Study: NCT04221035
Drug: Temozolomide 100 MG
Normalized name: temozolomide 100 MG
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m²/Day
Study: NCT04221035
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m²/jour de J0 à J4
Study: NCT03471871
Drug: Lemborexant 25 mg
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Study: NCT03471871
Drug: Lemborexant 10 mg
Normalized name: lemborexant 10 MG
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Study: NCT04221035
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
Study: NCT03750656
Drug: Hyoscyamine
Normalized name: Hyoscyamine
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
Study: NCT03750656
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
Study: NCT04513704
Drug: Oral Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
Study: NCT02770664
Drug: LC28-0126 Dose C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LC28-0126 Dose C
Study: NCT00635817
Drug: Leuprolide acetate 11.25 mg
Normalized name: leuprolide acetate 11.25 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
Study: NCT00635817
Drug: Leuprolide acetate 30 mg
Normalized name: leuprolide acetate 30 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
Study: NCT06434428
Drug: dexmedetomidine (IV)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of IV dexmedetomidine
Study: NCT06434428
Drug: dexmedetomidine (IN)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of IN dexmedetomidine
Study: NCT00819910
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone 8mg daily for 12 weeks
Study: NCT00819910
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 145 mg daily for 12 weeks
Study: NCT00506545
Drug: SCH 619734
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
Study: NCT01791803
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: free one month supply after hospital discharge
Study: NCT03376477
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
Study: NCT03376477
Drug: Prevnar13
Normalized name: Prevnar 20
DrugBank: Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
Study: NCT02023684
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: surgical bed Irrigation Lidocaine 0.5%, 40ml
Study: NCT00013650
Drug: Cyclophosphamate
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01912495
Drug: Boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04472767
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04472767
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04472767
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00389519
Drug: ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once a day oral ramipril capsules given for 4 weeks
Study: NCT00817050
Drug: Mometasone Furoate Nasal Spray
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
Study: NCT00817050
Drug: fluticasone nasal spray
Normalized name: fluticasone Metered Dose Nasal Spray
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose (2 sprays in each nostril) of fluticasone nasal spray
Study: NCT03772964
Drug: MetFORMIN Hydrochloride ER
Normalized name: MetFORMIN Hydrochloride ER
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
Study: NCT02023684
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: surgical bed Irrigation Ropivacaine 0.2%, 40ml
Study: NCT00780754
Drug: dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg
Study: NCT05386784
Drug: Raloxifene plus cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabone D ( Raloxifene 60mg + Cholecalciferol 800 IU ) 1 Capsule once daily
Study: NCT05386784
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 oral base drop, 4 drops once daily (800 IU)
Study: NCT03144804
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
Study: NCT01207908
Drug: IGF-1
Normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
Study: NCT01385280
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00822536
Drug: Aspirin and Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aspirin \<= 325 mg/j Clopidogrel = 75 mg /j
Study: NCT00822536
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin : \<= 325 mg/j
Study: NCT00241592
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00030862
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00030862
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02177682
Drug: Afuresertib
Normalized name: Afuresertib
DrugBank: Afuresertib (DB11648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
Study: NCT02828930
Drug: Idasanutlin
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
Study: NCT00644488
Drug: BMS-641988 (AR#2)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
Study: NCT02828930
Drug: [13C]-radiolabeled Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
Study: NCT02828930
Drug: [14C]-radiolabeled Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
Study: NCT01030679
Drug: CKD-501 1mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/tablet, orally, 1 tablet once daily for 8 weeks
Study: NCT01030679
Drug: CKD-501 2mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/tablet, orally, 1 tablet once daily for 8 weeks
Study: NCT02570893
Drug: Paclitaxel and carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02170870
Drug: Exendin 9-39
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
Study: NCT02032498
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
Study: NCT03224325
Drug: TAK-831 Suspension
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 Suspension.
Study: NCT02864381
Drug: Andecaliximab
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg administered via IV infusion
Study: NCT02864381
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/kg administered via IV infusion
Study: NCT02693041
Drug: probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.